Get the Stockscreener App
5.81
5.53%
-0.34
After Hours:
5.80
-0.010
-0.17%
Candel Therapeutics Inc stock is traded at $5.81, with a volume of 787.17K.
It is down -5.53% in the last 24 hours and up +6.41% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$6.15
Open:
$6.09
24h Volume:
787.17K
Relative Volume:
0.82
Market Cap:
$273.56M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-3.4379
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
+13.92%
1M Performance:
+6.41%
6M Performance:
-28.97%
1Y Performance:
-1.69%
1-Day Range:
$5.78
$6.1183
1-Week Range:
$4.8619
$6.42
52-Week Range:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.81 | 273.56M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics Elects New Directors at Annual Meeting - TipRanks
Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Purchased by Squarepoint Ops LLC - Defense World
Candel Therapeutics appoints new board member ahead of BLA submission By Investing.com - Investing.com South Africa
Small cap wrap: HIVE Digital, TNR Gold, Candel Therapeutics... - Proactive financial news
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., To Board - citybiz
Candel Therapeutics, Inc. Appoints Maha Radhakrishnan to Its Board of Directors - marketscreener.com
Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board - Proactive financial news
Candel Therapeutics appoints new board member ahead of BLA submission - Investing.com
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewswire
Former Biogen Chief Medical Officer Joins Candel Board as Prostate Cancer Drug Nears FDA Filing - Stock Titan
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Bought by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Takes Position in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - MSN
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL St - GuruFocus
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL Stock News - GuruFocus
Deutsche Bank AG Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer - MSN
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
Candel Therapeutics (CADL) Gains on FDA RMAT Designation for CAN-2409 - GuruFocus
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy By Investing.com - Investing.com South Africa
(CADL) Trading Report - news.stocktradersdaily.com
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy By Stocktwits - Investing.com India
Small cap wrap: Midnight Sun Mining, MustGrow Biologics, Candel Therapeutics, HIVE... - Proactive financial news
Market movers: GameStop, Okta, Abercrombie, Candel Therapeutics... - Proactive financial news
Candel Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Prostate Cancer Drug - marketscreener.com
Candel stock gains after FDA RMT designation (CADL:NASDAQ) - Seeking Alpha
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On? - Benzinga
Candel Therapeutics get FDA’s RMAT designation for prostate cancer therapy - Proactive financial news
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy - Investing.com Australia
Candel Therapeutics (CADL) Receives RMAT Designation for CAN-2409 in Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics Receives FDA RMAT Designation for CAN-2409 - TipRanks
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer - The Manila Times
Candel Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire
Breakthrough: FDA Fast-Tracks Revolutionary Prostate Cancer Therapy Showing 80% Complete Response Rate - Stock Titan
Northern Trust Corp Purchases 6,250 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results fo - GuruFocus
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results for Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation - The Manila Times
Candel Therapeutics to Host Investor Conference Call - GlobeNewswire
Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy - Proactive financial news
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
Candel Therapeutics: CAN-2409’s Promising Progress Deserves An Upgrade (NASDAQ:CADL) - Seeking Alpha
Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - MSN
Candel Therapeutics (NASDAQ:CADL) Upgraded at Wall Street Zen - Defense World
Small cap wrap: Excellon Resources, Candel Therapeutics, Forte Minerals... - Proactive financial news
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025 - Proactive financial news
Candel’s phase 3 trial for prostate cancer therapy shows promise By Investing.com - Investing.com Nigeria
Candel Therapeutics Unveils Promising Phase 3 Trial Results - TipRanks
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):